73 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
on the Innovation Advisory Council for Foundation Fighting Blindness and the Editorial Board of Journal of Ocular Pharmacology and Therapeutics.
Nirav Jhaveri
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
it may pursue could be significantly diminished.
Ocuphire may rely upon trade secrets, know-how, and continuing technological innovation to develop
8-K
EX-99.2
6n9rm
19 May 22
Regulation FD Disclosure
7:43am
8-K
EX-99.1
d13nrba8cay2isphwq6j
24 Mar 22
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update
8:17am
8-K
EX-99.1
ipo62y5k1vjg 4kss3
5 Jan 22
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
7:05am
8-K
EX-99.1
087wdca5l 00w
15 Nov 21
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12:00am
8-K
EX-99.1
1vvnro9e57achk2
12 Aug 21
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
7:31am
424B5
gj5dwo
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
xz5lvtntdwaf4nd7
7 May 21
Ocuphire Announces Financial Results for the First Quarter 2021 and Provides Corporate Update
4:01pm
424B5
06m6 5rmch
11 Mar 21
Prospectus supplement for primary offering
9:19am
8-K
EX-99.1
p54sdghgaq7gl4rlye0
11 Mar 21
Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update
9:12am